key: cord-0975647-zcnw958f authors: nan title: #AGS22: Offering the Latest to Learn in Medication Use, COVID-19 Research, Dementia Treatments, Health Equity & More date: 2022-03-09 journal: Geriatr Nurs DOI: 10.1016/j.gerinurse.2022.02.023 sha: 7f8a240b8d0c09c0609e2364132631804ba3493a doc_id: 975647 cord_uid: zcnw958f nan The past year has brought us many innovations in science and the ways we provide care. 2021 saw vaccines and new coronavirus disease 19 (COVID-19) treatments that have prevented illness and offered hope for those who become sick (U.S. Food and Drug Administration 4, 2021). As a society, we spent more time asking questions about the ways in which social factors can intersect with our health and even determine care outcomes and how individual and structural biases can affect those receiving 2 and providing 1 care. These breakthroughs and reflections offer plenty of opportunities for even more advancements in the ways we research, deliver, and advocate for health care. The American Geriatrics Society (AGS) is prepared to continue the momentum. At our 2022 AGS Annual Scientific Meeting (#AGS22) in Orlando, Florida, this May 12-14 (pre-conference day: Wednesday, May 11), more than 2,500 of the world's leading geriatrics experts will convene to advance research, education, clinical practice, and public policy supporting health, safety, and independence for the world's older adult population. #AGS22 will also offer post-meeting recordings for a selection of program sessions, available for those unable to travel to Orlando this May. Browse some highlights listed below from #AGS22's program schedule. Visit Meeting.AmericanGeriatrics.org to view the full program of more than 100 sessions, and to register for either in-person or recorded events. (Note, all times are ET.) Hospital Elder Life Program (HELP) Pre-Conference (5/11; 7:00 a.m.À5:30 p.m.). The HELP makes health systems safer and care more effective by preventing delirium, functional decline, falls, and other adverse outcomes among hospitalized older adults 3 . Attend the AGS CoCare Ò : HELP pre-conference to learn how to implement HELP in your hospital and ways to involve families and caregivers in improving patient care. Updates to the AGS Beers Criteria Ò for Potentially Inappropriate Medication Use in Older Adults (5/12; 10:15À11:15 a.m.). Updated every 3 years, the AGS Beers Criteria Ò serve as a critical tool in preventing adverse drug events and are an important tool for systems and individuals who seek to ensure high-quality health care for older adults. Originally conceived of by the late geriatrician Mark Beers, MD, the Beers Criteria catalogue medications that place older adults at an elevated risk for adverse drug events due to the physiological changes of aging or concurrent conditions. This program will present an overview of the updated 2022 criteria. Connecting Our Patients With Home and Community-Based Services: Current Issues With Access, Equity, and Policy (5/12; 11:30 a.m.À12:30 p.m.). Attend this session to become equipped with greater awareness of home and community-based services (HCBS), a better understanding of HCBS policies, and how to identify resources for patients, as well as promote equitable access to those resources. Dismantling Racism Brick by Brick: How Should Health Care Organizations Respond to Racism Against Health Care Workers? (5/12; 2:45À3:45 p.m.). This symposium considers how health care organizations should respond to overt racism expressed by patients against health care professionals, from the perspective of organizational leadership, including executive, legal, and policy experts. Henderson State-of-the-Art Lecture: Achieving Diversity in Study Populations: The Importance of Community Engagement (5/12; 4:00À5:00 p.m.). Sharon Brangman, MD, AGSF, will discuss the importance of designing research protocols that are inclusive of older adults who have been historically excluded or exploited in medical research. Dr. Brangman will present a model of community engagement that includes employing a community research liaison and a research accelerator to increase diversity in aging research. Long-Term Pulmonary, Cognitive, and Psychiatric Outcomes of COVID-19 (5/13; 10:30À11:30 a.m.). Presenters will review the most updated understanding of the biological impact of SARS-CoV-2 infection on various organ systems and share findings from their own longitudinal cohort studies, including hospitalized older and younger adults with and without critical illness. Presenters will review pulmonary, cognitive, and psychiatric symptoms, summarizing what clinicians should know about treating unique long-term health concerns. Riding Roller Coasters: The Ups and Downs of Public Policy During a Pandemic (5/13; 11:30 a.m.À12:30 p.m.). This session presents some of the major AGS achievements over the past 2 years as well as our ongoing AGS work throughout the pandemic. Learn about opportunities for influencing public policy and to hear the latest news about the Society's efforts. Evidence Geriatric Nursing journal homepage: www.gnjournal.com and late stages. Those living with dementia are especially in need of individualized care, and the challenging decision to prescribe and deprescribe medications often falls on geriatrics health professionals across a variety of settings. This symposium will offer the nurse, geriatrician, and pharmacist perspective. Evidence for the starting and discontinuing of medications using the 5Ms framework as a guide will be provided over the course of three sessions. Recognizing and Responding to Racial Microaggressions in Our Clinical Learning Environments: A Skill-Building Workshop (5/13; 2:45À3:45 p.m.). In this educational workshop, attendees will perform an interactive exercise to identify and respond to racial microaggressions in clinical settings. Learn strategies and skills to respond to and interrupt microaggressions. Chronic Pain Management (5/13; 4:00À5:00 p.m.). Pain is often poorly evaluated and managed in older adults. This session will review effective, evidence-based pharmacological and nonpharmacological strategies for managing chronic pain in older adults. Delirium Identification, Management, and Prevention: A Practical Up-to-Date Approach (5/14; 7:30À 8:30 a.m.). Get an up-todate review of delirium epidemiology, prediction and diagnostic tools, workup, and practical methods for implementing delirium reduction programs within health systems. It's Not Just Dialysis or Death, Part 2: The Challenges of Older Adults With Advanced Kidney Disease (5/14; 10:30À11:30 a.m.). In a follow-up to last year's well-received symposium describing necessary con-siderations when starting, stopping, or forgoing dialysis, this session will present a 10-minute vignette of an older adult with worsening kidney disease who is thinking about whether to initiate hemodialysis. Four experts with backgrounds in geriatrics, nursing, nutrition, and nephrology will each provide their insights regarding the situation, addressing issues with symptom management, lifestyle changes mandated with hemodialysis treatment, and best practices for advance care planning discussions regarding advanced kidney disease. Current Concepts of Diabetes Management in the Post-Acute and Long-Term Care Setting (5/14; 11:45 a.m.À12:45 p.m.). Learn to develop individualized care plans that include appropriate intensity of treatment and selection of hypoglycemic agents that reduce the risk of hypoglycemia in older adults. Recognizing and Addressing Racial Disparities in Acute and Long-Term Care Settings: Measurement Differences and Clinical Outcomes (5/14; 1:00À2:00 p.m.). Moderated by Barbara Resnick, PhD, CRNP, this symposium will raise awareness of current disparities in quality of care and clinical outcomes in Black versus White older adults with dementia in nursing home settings. An Update on Alzheimer's Disease Diagnosis and Therapeutics (5/14; 8:45À10:15 a.m.). In June 2021, the FDA approved Biogen's drug aducanumab (Aduhelm TM ) for use in treating people with Alzheimer's disease. This session will review the evidence and controversies surrounding aducanumab, including the implications for other pharmaceutical companies to potentially seek accelerated FDA approval for anti-amyloid therapy based on surrogate (biomarker) endpoints. Attendees will learn how best to choose appropriate patients for aducanumab and how to use the treatment. There will also be a discussion about precision medicine being increasingly applied to older adults in determining their risk of future dementia and other neurodegenerative diseases. We hope to see you in Orlando. Discourse of race and racism in nursing: An integrative re-view of literature End-ing structural racism in the US health care system to eliminate health care inequities The bundled hospital elder life program-HELP and HELP in home care-and its association with clinical outcomes among older adults discharged to home healthcare Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of covid-19